Combining microchip engineering techniques with cutting-edge gene profiling, scientists at Columbia University have developed a new way to study drug responses in living slices of human brain tumor cells.
A new noninvasive neurostimulation technique capable of reaching deep regions of the brain has been used to elucidate the brain’s pain mechanisms, with promising clinical applications in neurology and psychiatry.
For the first time, researchers have used an advanced AI model that understands both images and language, allowing them to model dyslexia, paving the way for potential new treatments.
The newly approved HIV drug Idvynso will also help Merck diversify as loss of exclusivity looms over its top-selling product, the mega-blockbuster cancer drug Keytruda.
In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for resubmission remains uncertain.
The ArteraAI prostate biopsy assay predicts the risk of prostate cancer progression.
Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency related reintervention rate of 1.3 per patient year.
Johnson & Johnson (NYSE:JNJ) announced today that it received CE mark approval for its new Ethicon 4000 surgical stapler.
Philips (NYSE:PHG) announced today that it received FDA 510(k) clearance for its Rembra platform of scanning systems.
Sonorous Neurovascular announced today that it received FDA 510(k) clearance for its BosCATH next-generation neurovascular catheter.